dr. jhaveri discusses the utility of t-dm1 in the neoadjuvant setting
Published 10 years ago • 294 plays • Length 0:56Download video MP4
Download video MP3
Similar videos
-
4:04
neoadjuvant t-dm1 in her2 early breast cancer
-
0:51
dr. jhaveri on the use of trastuzumab biosimilars in breast cancer
-
0:57
dr. louis weiner on the t-dm1 mechanism of action in her2-positive breast cancer
-
4:52
emilia trial: t-dm1 in metastatic breast cancer
-
1:55
dr. jhaveri discusses the potential of immunotherapy in tnbc
-
1:38
t-dm1 plus pertuzumab in the marianne trial
-
2:00
dr. esteva discusses t-dm1 in her2-positive breast cancer
-
3:58
frontline t-dm1 in her2-positive metastatic breast cancer
-
1:52
dr. mark pegram discusses earlier treatment with t-dm1
-
0:33
expanding treatment in the neoadjuvant setting
-
1:42
dr. denduluri on the role of neoadjuvant therapy in her2 breast cancer
-
1:06
dr. edith perez on the antibody-drug conjugate t-dm1
-
0:52
dr. julie gralow discusses the antibody drug conjugate t-dm1 for breast cancer
-
1:04
dr. perez on t-dm1 and the marianne trial
-
3:02
dr. jhaveri discusses potential targets of inflammatory breast cancer
-
8:03
refining neoadjuvant chemotherapy for her2 breast cancer
-
1:42
the case for neoadjuvant pembrolizumab in tnbc
-
1:18
dr. hamilton discusses the katherine trial in her2 breast cancer
-
49:47
understanding the treatment continuum with dr. jay jhaveri - zero prostate cancer summit 2022